(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

Aptiv is one of a number of multinationals gathering in Shanghai to test the pulse of China's smart manufacturing market, ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market Merck experts to provide ...

The 11th Edition of Merck Foundation Africa Asia Luminary was officially inaugurated by The President of the United Republic of Tanzania, H.E. Dr. SAMIA SULUHU HASSAN, Chairman of Merck Foundation ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Merck's recently approved vaccine, however, gives Pfizer some major competition. The shot, called Capvaxive, protects against bacterial strains that cause about 84% of cases of adult pneumoccocal ...

The shots are also suggested for certain adults and children who are immunocompromised. A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...